Introduction
============

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, and its morbidity and mortality have demonstrated an ever-pressing health trend in China, according to a recent annual report of cancer epidemiology.[@b1-ott-10-4665] Considerable progress has been made in the diagnosis and treatment of HCC, including novel target chemotherapy, hyperemia therapy, and other multidisciplinary managements.[@b2-ott-10-4665],[@b3-ott-10-4665] However, the prognosis of patients with HCC remains extremely poor, which is mainly challenged by metastasis and recurrence of neoplasms. Consequently, there is an urgent need to provide effective strategies for the diagnosis and treatment of tumors. Molecular bio-techniques are preferred among the newer strategies, as emerging evidence has showed that genetic alterations were implicated in the HCC cell proliferation and migration processes.[@b4-ott-10-4665]--[@b6-ott-10-4665] Unfortunately, only a few of these biomarkers are satisfactory. Therefore, continual efforts in screening new biomarkers for HCC remain necessary.

Stomatin-like protein 2 (SLP-2, also known as STOML2), a member of the stomatin superfamily, is a major protein which locates on the mitochondrial inner membrane. This protein does not contain a NH2-terminal hydrophobic domain compared to other family members. Meanwhile, SLP-2 may play a major role in organizing sphingolipid and cholesterol-rich lipid rafts, regulating ion channel conductance, and linking other integral membrane proteins to the peripheral cytoskeleton.[@b7-ott-10-4665] The SLP-2 protein was found to be overexpressed in many human cancer tissues, including papillary thyroid carcinoma,[@b8-ott-10-4665] esophageal cancer,[@b9-ott-10-4665],[@b10-ott-10-4665] gastric cancer,[@b11-ott-10-4665] endometrial adenocarcinoma,[@b12-ott-10-4665] and breast cancer.[@b13-ott-10-4665] Emerging evidences showed that SLP-2 possessed an ability to promote proliferation and adhesion in the esophageal squamous cell carcinoma cell line TE12.[@b9-ott-10-4665],[@b10-ott-10-4665] These results suggested that SLP-2 was a novel cancer-related gene, and a potential drug target to block proliferation and migration in tumor cells. However, expression of SLP-2 and its clinical significance in HCC has not yet been uncovered. Thus, we conducted the present study to analyze the level of SLP-2 expression in HCC tissues, as well as its associated clinical implications. In addition, for better mechanistic understanding of how SLP-2 is involved in carcinogenesis, we conducted further experiments to study the effects of SLP-2 on cell proliferation, apoptosis, migration, invasion, and the EMT process in HCC cell lines.

Materials and methods
=====================

Ethics statement
----------------

This study was approved by the Second Affiliated Hospital of Shantou University Medical College Ethics Committee according to the Helsinki Declaration. Informed consent was obtained either from the patient or their next of kin for all tissue samples used.

Tissue samples
--------------

Between 2012 and 2016, HCC tissue and adjacent normal liver tissues were collected from 60 patients who underwent radical surgeries for HCC in the Second Affiliated Hospital of Shantou University Medical College (Guangdong, People's Republic of China). Pathological features of these tissue samples were evaluated by the Department of Pathology, The Second Affiliated Hospital, according to the World Health Organization standards. Characteristics and follow-up data of patients were obtained from medical records.

Cell lines
----------

L02, HepG2, HCCLM3, MHCC97H, and BEL-7702 cell lines were purchased from Shanghai Cell Bank of the Chinese Academy of Science (Shanghai, People's Republic of China). All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (FBS; Gibco), and then incubated with 5% CO~2~ at 37°C in a humidified atmosphere.

Quantitative reverse transcription PCR
--------------------------------------

Total RNA of the 60 paired fresh tissue samples, extracted with RNAiso Plus reagent (Takara, Tokyo, Japan), was reversely transcribed into cDNA by Prime Script RT Master Mix (Takara) according to the manufacturer's protocol. The relative mRNA level was assessed by quantitative polymerase chain reaction (qPCR) with SYBR Premix Ex Taq kit (Takara) and normalized to GAPDH with the following primers: SLP-2 forward (F), 5′-CCAGCAGAGCAGCCTCATC-3′ and reverse (R), 5′-TCCTTGAGTGACGCCAGGA-3′. GAPDH F, 5′-CAGGAGGCATTGCTGATGAT-3′ and R, 5′-GAAGGCTGGGGCTCATTT-3′. Changes in the expression were calculated by the 2^−ΔΔCT^ method. For statistical analysis, these 60 patients were grouped into high and low categories based on the median of relative SLP2 expression.[@b13-ott-10-4665]

Immuohistochemistry
-------------------

For immunohistochemistry (IHC), 4 μm-thick sections were cut from 10% formalin-fixed paraffin-embedded tissue samples. These sections were routinely deparaffinized, hydrated, and repaired in a microwave for 10 min, treated in 3% H~2~O~2~ to eliminate endogenous peroxidase for 15 min, then subjected to 10% normal goat non-immune block for 30 min, and incubated with rabbit anti-human SLP-2 antibody (1:200; Cat NO 10348-1-AP, Proteintech, Rosemont, IL, USA) at 4°C overnight. After washing with PBS, the sections were incubated with streptavidin-peroxidase conjugated goat anti-rabbit secondary antibody (ZSGB, People's Republic of China). After extensive washing, 3,3-diaminobenzidine (DAB, ZSGB) was used for visual reaction. Immunostaining was reviewed by two pathologists independently. SLP-2 protein expression in 60 paired tissue samples were classified into positive and negative groups according to Zhao et al.[@b14-ott-10-4665]

siRNA transfection
------------------

HepG2 and HCCLM3 cells were cultured in six-well plates. The siRNAs targeting SLP-2 and negative control (NC) were transfected in the cells using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA) and Opti-MEM (Thermo Fisher Scientific) following the manufacturer's instruction. The sequences of siRNAs and NC were as follows: siRNA-1, 5′-GCAGUCAGCCGUAACUCUUTT-3′ and 5′-AAGAGUUACGGCUGACUGCTT-3′; siRNA-2, 5′-GCCUGCGAUACGAGAUCAATT-3′ and 5′-UUGAUCUCGUAUCGCAGGCTT-3′; NC, 5′-UUCUCCGAA CGUGUCACGUTT-3′ and 5′-ACGUGACACGUUCG GAGAATT-3′.

Cell proliferation assay
------------------------

A total of 2×10^3^ cells per well were seeded in 96-well plates for 24 h, transfected with the indicated siRNAs, and the cell number was then assessed by Cell Counting Kit 8 (CCK-8; KeyGEN, Nanjing, People's Republic of China) following the kit assay protocol at 0, 24, 48, 72, and 96 h after transfection. Briefly, 10 μL of CCK 8 solution was added to each well and incubated for 2 h at 37°C. The solution was then measured spectrophotometrically at 450 nm.

Cell apoptosis assay
--------------------

Transfected cells were collected and treated with Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI). Apoptosis Detection Kit (KeyGEN) according to the manufacturer's instructions. Flow cytometry was undertaken by BD FACSCalibur flow cytometer systems (Becton Dickinson, Franklin Lakes, NJ, USA).

Transwell migration and invasion assay
--------------------------------------

After transfection with the indicated siRNAs for 48 h, 5×10^4^ cells were harvested in 200 μL serum-free medium, and added to the upper chambers with 8 μm pores in 24-well plates (Corning Incorporated, Corning, NY, USA). The migration was induced by 10% FBS medium in the lower chambers. After 24 h, the cells were fixed in 4% paraformaldehyde and stained with 0.5% crystal violet. The numbers of migrated cells were counted in five different fields under an inverted microscope (Nikon, Tokyo, Japan). For the invasion assay, all conditions were as described above after the inserts were pre-coated with 50 μL Matrigel (1:8; Corning Incorporated).

Western blotting assay
----------------------

Western blotting (WB) was carried out using rabbit anti-human antibodies including E-Cadherin (1:1,000; Cat No 9782T), N-Cadherin (1:1,000), Vimentin (1:1,000; Cat No 9782T), Snail (1:1,000; Cat No 9782T), and β-actin (1:1,000; Cat No 9782T, Cell Signaling Technology, Boston, MA, USA). Transfected cells were lysed in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitor; 30 μg total protein was subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore Corp, Billerica, MA, USA). Non-specific antibodies were blocked by 5% BSA in PBST for 1 h. The membranes were then incubated with primary antibodies at 4°C overnight, and subsequently incubated with HRP-conjugated goat anti-rabbit secondary antibody (1:1,000; Cat. No 9782T, Cell Signaling Technology) for 1 h. The immunoblotted proteins were detected by enhanced chemiluminescence (ECL; Millipore).

Statistical analysis
--------------------

All data were analyzed with the SPSS version 19 for Windows (SPSS, Chicago, IL, USA) and GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). Levels of SLP-2 mRNA in HCC tissues and in adjacent normal tissues were compared by the Mann--Whitney test. Correlations between SLP-2 expression and clinicopathological parameters were evaluated by the *χ*^2^ test. Tumor-free survival was analyzed using the Kaplan--Meier method, and the differences was evaluated by the log-rank test. Comparisons among multiple groups were determined using one-way ANOVA. *P*\<0.05 was considered to indicate a statistically significant difference.

Results
=======

SLP-2 exhibited overexpression in HCC
-------------------------------------

To investigate the role of SLP-2 in HCC, we first detected the levels of SLP-2 mRNA and protein expression in 60 cases of HCC tissues and adjacent normal tissues, respectively. On qRT-PCR, an elevated SLP-2 mRNA level was observed in cancerous tissues, compared with the adjacent normal tissues ([Figure 1A](#f1-ott-10-4665){ref-type="fig"}). SLP-2 upregulation (tumor/non-tumor ≥1) was found in 39 cases (65%, [Figure 1B](#f1-ott-10-4665){ref-type="fig"}). With IHC, positive expression of the SLP-2 protein was detected in the cytoplasm of hepatocytes ([Figure 1C](#f1-ott-10-4665){ref-type="fig"}), with the positive rate of SLP-2 in cancerous tissues being significantly higher than that in the adjacent normal tissues (56.7% vs 13.3%). Furthermore, we found that SLP-2 was overexpressed in HCC cells compared to that in the normal liver cell line L02 ([Figure 1F](#f1-ott-10-4665){ref-type="fig"}).

Overexpression of SLP-2 predicts poor prognosis in patients with HCC
--------------------------------------------------------------------

To evaluate the clinical benefits of SLP-2, the expression data from tumor tissue samples were subjected to statistical correlation with various clinicopathological parameters, and the results were summarized in [Tables 1](#t1-ott-10-4665){ref-type="table"} and [2](#t2-ott-10-4665){ref-type="table"}. Upregulation of SLP-2 mRNA was strongly associated with AFP level, tumor size, metastasis, and recurrence. Similar results were observed in the SLP2 protein analysis. Positive expression of SLP-2 was significantly associated with tumor size, TNM stage, metastasis, and recurrence. The prognostic potential of SLP-2 was evaluated by the Kaplan--Meier method with log-rank test, and high expression of SLP-2 associated with poor tumor-free survival ([Figure 1D and E](#f1-ott-10-4665){ref-type="fig"}).

Silencing SLP-2 inhibits cell proliferation and induces cell apoptosis
----------------------------------------------------------------------

Our statistical data showed that overexpression of SLP-2 was correlated with tumor size and metastasis, which inspired us to examine the functional role of SLP-2 in HCC cell lines. To investigate the effects of SLP-2 on the proliferation of HCC cells, siRNA-mediated knockdown of SLP2 was employed in the HepG2 and HCCLM3 cells. As shown by qRT-PCR and WB results ([Figure 2A](#f2-ott-10-4665){ref-type="fig"}), two series of siRNA targeting SLP-2 efficiently reduced SLP-2 expression in HepG2 and HCCLM3 cells. Furthermore, a CCK8 assay indicated that cell proliferation was significantly inhibited after 48-h SLP-2-specific siRNA treatment in two HCC cell lines ([Figure 2B and C](#f2-ott-10-4665){ref-type="fig"}). Evasion of apoptosis results in unlimited growth of cancer cells. After knockdown of SLP-2, apoptosis of HepG2 and HCCLM3 cells was found to remarkably increase ([Figure 2D](#f2-ott-10-4665){ref-type="fig"}). It seemed that SLP-2 regulates cell proliferation by inducing apoptosis.

Silencing SLP-2 represses cell migration and invasion
-----------------------------------------------------

Next, we examined the role of SLP-2 in HCC cell migration and invasion by a transwell migration assay. As shown in [Figure 3A--D](#f3-ott-10-4665){ref-type="fig"}, both the number of migrated and invaded HepG2 and HCCLM3 cells that got through the chambers decreased significantly in the SLP-2 knockdown group, indicating that SLP-2 was a tumor-promoting gene in HCC, and might strengthen the migration and invasion of HCC cells.

Silencing SLP-2 suppresses the EMT process
------------------------------------------

EMT has been increasingly recognized to occur during the development of HCC. To identify whether SLP-2 is involved in the process of EMT and consequently promotes HCC metastasis, we next investigated the role of SLP-2 in HCC cell EMT and found EMT results in loss of epithelial markers and gain of mesenchymal markers. Western blot showed that expression of E-cadherin was upregulated, whereas N-cadherin, Vimentin, and Snail were downregulated in SLP-2 knockdown groups ([Figure 3E](#f3-ott-10-4665){ref-type="fig"}). Therefore, we inferred that SLP-2 may prompt EMT processes in HCC.

Discussion
==========

Hepatectomy and liver transplantation are preferred therapeutic options for HCC that, however, cannot guarantee full recovery. The main factors responsible for this phenomenon are the biological characteristics of metastasis and recurrence in HCC.[@b15-ott-10-4665]--[@b20-ott-10-4665] Tumorigenesis results from multifactorial, multistep, multigene, and multi-mutation elements. It would be beneficial to, first, discover new biomarkers involved in HCC oncogenesis and progress that predict early tumor recurrence, then clarify their molecular mechanisms, and design better targeted therapy.[@b3-ott-10-4665]

SLP-2 was a peripheral cytoskeleton-related protein and was found to be highly associated with multiple malignancies. Recent studies on gastric cancer, endometrial cancer, breast cancer, laryngeal cancer, glioma, and ovarian cancer have all shown that the SLP-2 was overexpressed and actively involved during cancer development and progression.[@b7-ott-10-4665]--[@b12-ott-10-4665],[@b14-ott-10-4665] However, very little is known regarding its oncogenic potential in HCC. In the present study, we initially investigated the SLP-2 expression status in HCC at both the mRNA and protein levels. The results of the immunohistochemistry and qRT-PCR study were cross-supported, verifying that SLP-2 was markedly overexpressed in HCC tissues as compared with normal counterparts. Further statistical analysis indicated that overexpression of SLP-2 was significantly associated with APF levels, tumor size, TNM stage, metastasis, and recurrence of patients with HCC. These findings suggested that SLP-2 was a potential oncogene to predict poor prognosis of patients with HCC.

SLP-2 is a novel but unusual member of the stomatin gene superfamily.[@b21-ott-10-4665],[@b22-ott-10-4665] The human stomatin protein family comprises five members, including stomatin, SLP-1, SLP-2, SLP-3, and the kidney-specific protein podocin. SLP-2 and stomatin share a stomatin-homology region and are part of the much larger SPFH (stomatin--prohibitin--flotillin--HflK/C) superfamily, whereas SLP-2 lacks the typical amino-terminal transmembrane domain present in other stomatins.[@b23-ott-10-4665] Emerging evidence have shown that stomatins were involved in the organization of the peripheral cytoskeleton, the formation of sphingolipid- and cholesterol-rich lipid rafts, and the assembly of ion channels and mechanosensation receptors.[@b24-ott-10-4665],[@b25-ott-10-4665] Furthermore, SLP-2 have been shown to enhance invasiveness in glioma and esophageal squamous cell carcinoma (ESCC) cells, potentially through the upregulation of matrix metalloproteinase 9 (MMP-9), mainly through an NF-κB signaling pathway.[@b10-ott-10-4665],[@b26-ott-10-4665] Our research also suggested SLP-2 highly correlated with cell motility abilities, as the tumor size, metastasis, and recurrence of HCC were both significantly associated with SLP-2. However, the exact mechanism underlying SLP-2 involvement in cell motility abilities in HCC remains unclear, including cell proliferation, apoptosis, migration, and invasion.

Previous studies have suggested that knockdown of SLP-2 may dramatically reduce the growth rate of tumor cells in vitro and in vivo and inhibit cell attachment.[@b10-ott-10-4665] In order to explore the effect of SLP-2 on HCC, we used SLP-2-targeting siRNAs to knockdown SLP-2 in the HCC cell lines to study the effect of SLP-2 downregulation. The results showed that cell proliferation after SLP-2 silencing was downregulated compared with the control group, which suggested that SLP-2 might promote cell proliferation in HCC cell lines. Consistently, we also found that depletion of SLP-2 suppressed HCC cell lines proliferation in vivo, as the tumor growth on mice was inhibited by 50% in SLP-2 downregulated group. Thus, SLP-2 siRNA induced significantly more cell apoptosis (twofold higher) in HepG2 cells than did the control group. Moreover, SLP-2 siRNA did inhibit cell migration and invasion abilities. Taken together, SLP-2 depletion might result in changes in the capacity of HCC cells, including cell proliferation, apoptosis, migration, and invasion.

Previous studies have shown that metastasis was a characteristic feature of HCC and a principal factor related to poor prognosis in patients with HCC.[@b2-ott-10-4665],[@b18-ott-10-4665]--[@b20-ott-10-4665] Consequently, identification of the molecular mechanisms responsible for control of the metastatic potential of HCC is crucial in order to inhibit these processes. EMT under stimulation is correlated with tumor metastasis. During EMT, epithelial cells lose polarity and gain greater ability for migration.[@b27-ott-10-4665]--[@b29-ott-10-4665] A complex network of transcriptional regulation orchestrates the process of EMT during development, and distinct aspects of the physiologic changes characterizing EMT are regulated by the coordinated and overlapping activity of a number of transcriptional factors.[@b3-ott-10-4665],[@b30-ott-10-4665]

In this study, cell-function experiments suggested SLP-2 might be associated with metastasis. In order to discover its further mechanisms, we tested EMT-related proteins and found that knockdown of SLP-2 upregulated protein expression levels of E-cadherin and downregulated N-cadherin, Vimentin, and Snail, which conferred evidence that SLP-2 is involved in the EMT process.

In summary, this study for the first time showed that SLP-2 is overexpressed in HCC tissues and is negatively associated with the prognosis of patients with HCC. We found that SLP-2 knockdown significantly inhibited tumor cell proliferation, apoptosis, migration, invasion, and EMT progression. Our study results shed a new light on HCC pathogenesis, and SLP-2 might be utilized as a potential novel target for effective treatment of HCC. Meanwhile, prospective studies and enlargement of the evidence base with larger samples should be conducted to draw definitive conclusions and validate the diagnostic value of SLP-2 in HCC.
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![Overexpression of SLP-2 occurs in HCC and predicts poor prognosis in patients with HCC.\
**Notes:** (**A**) SLP-2 mRNA was significantly upregulated in HCC tumor (T) versus non-tumorous (NT) tissues, as detected by qRT-PCR. \*\**P*\<0.01. (**B**) Upregulation of SLP-2 mRNA was found in (39/60) 65% of HCC cases. Data represent the log2 ratio of SLP-2 mRNA level in HCC tissues, as compared to the corresponding non-tumorous tissues. (**C**) Representative image of (IHC) for SLP-2 in clinical HCC samples showed that the SLP-2 protein was located in the cytoplasm of liver cells. Original magnification, ×400. (**D** and **E**) Patients with SLP-2 mRNA or protein overexpression had lower tumor-free survival rate (*P*=0.0224 and *P*=0.0017, respectively). (**F**) SLP-2 was upregulated in HCC cell lines, compared to L02. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.\
**Abbreviations:** HCC, hepatocellular carcinoma; IHC, immunohistochemistry; SLP-2, stomatin-like protein 2.](ott-10-4665Fig1){#f1-ott-10-4665}

![Knockdown of SLP-2 inhibits cell proliferation and induces cell apoptosis in vitro.\
**Notes:** (**A**) SLP-2 expression was successfully knocked down by siRNAs detected by qRT-PCR and Western blot. \*\**P*\<0.01 vs blank. (**B** and **C**) Knockdown of SLP-2 inhibited cell proliferation in both HepG2 and HCCLM3 cells. (**D**) Knockdown of SLP-2 induced cell apoptosis of HepG2 and HCCLM3 cells. \*\*\**P*\<0.001 vs blank.\
**Abbreviations:** FITC-A, fluorescein isothiocyanate-A; NC, negative control; SLP-2, stomatin-like protein 2.](ott-10-4665Fig2){#f2-ott-10-4665}

![Depletion of SLP-2 represses cell migration, invasion, and EMT in vitro.\
**Notes:** (**A**--**D**) Knockdown of SLP-2 represses cell migration and invasion in both HepG2 and HCCLM3 cells, when compared with control groups. \*\**P*\<0.01 vs blank. (**E**) Expression of EMT-related proteins detected by Western blotting in HCC cells after SLP-2 knockdown.\
**Abbreviations:** EMT, epithelial--mesenchymal transition; HCC, hepatocellular carcinoma; NC, negative control; SLP-2, stomatin-like protein 2.](ott-10-4665Fig3){#f3-ott-10-4665}

###### 

Correlation between SLP-2 mRNA expression and the clinicopathological parameters

  Variable          Cases, n   SLP-2 mRNA expression   *χ*^2^ value   *P*-value   
  ----------------- ---------- ----------------------- -------------- ----------- -------
  Gender                                                              0.097       1.000
   Male             55         29                      26                         
   Female           5          3                       2                          
  Age                                                                 1.176       0.472
   \<60 years       51         27                      24                         
   ≥60 years        9          3                       6                          
  AFP                                                                 6.696       0.010
   \<400 μg/L       32         11                      21                         
   ≥400 μg/L        28         19                      9                          
  Tumor size                                                          4.207       0.040
   ≤5 cm            29         12                      17                         
   \>5 cm           31         21                      10                         
  Tumor amount                                                        0.693       0.405
   Solitary         19         11                      8                          
   Multiple         41         19                      22                         
  Differentiation                                                     0.172       0.918
   Well             8          4                       4                          
   Moderate         34         15                      19                         
   Poor             18         7                       10                         
  BCLC stage                                                          0.521       0.771
   A                34         16                      17                         
   B                8          3                       5                          
   C                17         9                       8                          
  TNM stage                                                           0.069       0.793
   I/II             25         12                      13                         
   III/IV           35         18                      17                         
  Metastasis                                                          5.475       0.019
   Yes              26         20                      6                          
   No               34         16                      18                         

**Abbreviations:** AFP, α-fetoprotein; SLP-2, stomatin-like protein 2; TNM, tumor, node, metastasis; BCLC, Barcelona Clinic Liver Cancer.

###### 

Correlation between SLP-2 protein expression and clinicopathological parameters

  Variable          Cases, n   SLP-2 protein expression   *χ*^2^ value   *P*-value   
  ----------------- ---------- -------------------------- -------------- ----------- -------
  Gender                                                                 0.336       0.562
   Male             51         29                         22                         
   Female           9          5                          4                          
  Age                                                                    0.266       0.606
   \<60 years       49         27                         22                         
   ≥60 years        11         7                          4                          
  AFP                                                                    2.986       0.084
   \<400 μg/L       44         22                         22                         
   ≥400 μg/L        16         12                         4                          
  Tumor size                                                             5.071       0.024
   ≤5 cm            27         11                         16                         
   \>5 cm           33         23                         10                         
  Tumor amount                                                           0.017       0.896
   Solitary         48         27                         21                         
   Multiple         12         7                          5                          
  Differentiation                                                        3.935       0.140
   Well             13         5                          8                          
   Moderate         34         19                         15                         
   Poor             13         10                         3                          
  BCLC stage                                                             7.946       0.019
   A                39         17                         22                         
   B                8          6                          2                          
   C                13         11                         2                          
  TNM stage                                                              9.774       0.002
   I/II             30         11                         19                         
   III/IV           30         23                         7                          
  Metastasis                                                             13.575      0.000
   Yes              20         16                         24                         
   No               40         18                         2                          

**Abbreviations:** AFP, α-fetoprotein; SLP-2, stomatin-like protein 2; TNM, tumor, node, metastasis; BCLC, Barcelona Clinic Liver Cancer.
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